{
    "organizations": [],
    "uuid": "a8eef94b2fa123def8dd45ad5a44e8d9701c45ba",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-argos-obtains-option-to-license-pd/brief-argos-obtains-option-to-license-pd1-checkpoint-inhibitors-idUSFWN1PV1BQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - Argos Therapeutics Inc:\n* ARGOS OBTAINS OPTION TO LICENSE PD1 CHECKPOINT INHIBITORS\n* ARGOS THERAPEUTICS INC - ENTERED INTO AN OPTION AGREEMENT WITH PHARMSTANDARD INTERNATIONAL, S.A. AND ACTIGEN LIMITED\n* ARGOS THERAPEUTICS INC - UNDER DEAL, CO HAS OPTION TO LICENSE GROUP OF FULLY HUMAN ANTI-PD1 MONOCLONAL ANTIBODIES AND RELATED TECHNOLOGY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T05:48:00.000+02:00",
    "crawled": "2018-02-07T00:02:35.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "argo",
        "therapeutic",
        "inc",
        "argo",
        "obtains",
        "option",
        "license",
        "pd1",
        "checkpoint",
        "inhibitor",
        "argo",
        "therapeutic",
        "inc",
        "entered",
        "option",
        "agreement",
        "pharmstandard",
        "international",
        "actigen",
        "limited",
        "argo",
        "therapeutic",
        "inc",
        "deal",
        "co",
        "option",
        "license",
        "group",
        "fully",
        "human",
        "monoclonal",
        "antibody",
        "related",
        "technology",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}